<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2025//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_250101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">36577847</PMID><DateCompleted><Year>2023</Year><Month>03</Month><Day>07</Day></DateCompleted><DateRevised><Year>2023</Year><Month>06</Month><Day>07</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1348-4214</ISSN><JournalIssue CitedMedium="Internet"><Volume>46</Volume><Issue>3</Issue><PubDate><Year>2023</Year><Month>Mar</Month></PubDate></JournalIssue><Title>Hypertension research : official journal of the Japanese Society of Hypertension</Title><ISOAbbreviation>Hypertens Res</ISOAbbreviation></Journal><ArticleTitle>Optimizing antihypertensive therapy in patients with diabetes mellitus.</ArticleTitle><Pagination><StartPage>797</StartPage><EndPage>800</EndPage><MedlinePgn>797-800</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1038/s41440-022-01150-5</ELocationID><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Liu</LastName><ForeName>Wenhao</ForeName><Initials>W</Initials><AffiliationInfo><Affiliation>Department of Cardiovascular Medicine, The University of Tokyo, 7-3-1 Hongo, Bunkyo-ku, Tokyo, 113-8655, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Higashikuni</LastName><ForeName>Yasutomi</ForeName><Initials>Y</Initials><AffiliationInfo><Affiliation>Department of Cardiovascular Medicine, The University of Tokyo, 7-3-1 Hongo, Bunkyo-ku, Tokyo, 113-8655, Japan. yasutomihigashikuni@g.ecc.u-tokyo.ac.jp.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Sata</LastName><ForeName>Masataka</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Department of Cardiovascular Medicine, Tokushima University Graduate School, 3-18-15 Kuramoto-cho, Tokushima-shi, Tokushima, 770-8503, Japan.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016421">Editorial</PublicationType><PublicationType UI="D016420">Comment</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2022</Year><Month>12</Month><Day>28</Day></ArticleDate></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>Hypertens Res</MedlineTA><NlmUniqueID>9307690</NlmUniqueID><ISSNLinking>0916-9636</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000959">Antihypertensive Agents</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000806">Angiotensin-Converting Enzyme Inhibitors</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><CommentsCorrectionsList><CommentsCorrections RefType="CommentOn"><RefSource>Hypertens Res. 2023 Jan;46(1):128-135. doi: 10.1038/s41440-022-01051-7.</RefSource><PMID Version="1">36229537</PMID></CommentsCorrections></CommentsCorrectionsList><MeshHeadingList><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000959" MajorTopicYN="N">Antihypertensive Agents</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D001794" MajorTopicYN="N">Blood Pressure</DescriptorName><QualifierName UI="Q000502" MajorTopicYN="N">physiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006973" MajorTopicYN="Y">Hypertension</DescriptorName><QualifierName UI="Q000503" MajorTopicYN="N">physiopathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000806" MajorTopicYN="N">Angiotensin-Converting Enzyme Inhibitors</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D003920" MajorTopicYN="Y">Diabetes Mellitus</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Antihypertensive agents</Keyword><Keyword MajorTopicYN="N">Diabetes mellitus</Keyword><Keyword MajorTopicYN="N">Hypertension</Keyword><Keyword MajorTopicYN="N">Inflammation</Keyword><Keyword MajorTopicYN="N">Physiopathology</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2022</Year><Month>11</Month><Day>27</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2022</Year><Month>12</Month><Day>12</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2022</Year><Month>12</Month><Day>10</Day></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2022</Year><Month>12</Month><Day>29</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2023</Year><Month>3</Month><Day>8</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2022</Year><Month>12</Month><Day>28</Day><Hour>23</Hour><Minute>30</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">36577847</ArticleId><ArticleId IdType="doi">10.1038/s41440-022-01150-5</ArticleId><ArticleId IdType="pii">10.1038/s41440-022-01150-5</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Tatsumi Y, Ohkubo T. Hypertension with diabetes mellitus: significance from an epidemiological perspective for Japanese. Hypertens Res. 2017;40:795&#x2013;806.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/hr.2017.67</ArticleId></ArticleIdList></Reference><Reference><Citation>Grossman A, Grossman E. Blood pressure control in type 2 diabetic patients. Cardiovasc Diabetol. 2017;16:3.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s12933-016-0485-3</ArticleId></ArticleIdList></Reference><Reference><Citation>Gnanenthiran SR, Webster R, de Silva A, Maulik PK, Salam A, Selak V, et al. Reduced efficacy of blood pressure lowering drugs in the presence of diabetes mellitus&#x2013;results from the TRIUMPH randomised controlled trial. Hypertens Res. 2023;46:128&#x2013;35.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41440-022-01051-7</ArticleId></ArticleIdList></Reference><Reference><Citation>Webster R, Salam A, de Silva HA, Selak V, Stepien S, Rajapakse S, et al. Fixed low-dose triple combination antihypertensive medication vs usual care for blood pressure control in patients with mild to moderate hypertension in Sri Lanka: a randomized clinical trial. JAMA 2018;320:566&#x2013;79.</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/jama.2018.10359</ArticleId></ArticleIdList></Reference><Reference><Citation>Shen Y, Dai Y, Wang XQ, Zhang RY, Lu L, Ding FH, et al. Searching for optimal blood pressure targets in type 2 diabetic patients with coronary artery disease. Cardiovasc Diabetol. 2019;18:160.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s12933-019-0959-1</ArticleId></ArticleIdList></Reference><Reference><Citation>Low Wang CC, Hess CN, Hiatt WR, Goldfine AB. Clinical update: cardiovascular disease in diabetes mellitus: atherosclerotic cardiovascular disease and heart failure in type 2 diabetes mellitus - mechanisms, management, and clinical considerations. Circulation. 2016;133:2459&#x2013;502.</Citation><ArticleIdList><ArticleId IdType="doi">10.1161/CIRCULATIONAHA.116.022194</ArticleId></ArticleIdList></Reference><Reference><Citation>Ferrannini E, Buzzigoli G, Bonadonna R, Giorico MA, Oleggini M, Graziadei L, et al. Insulin resistance in essential hypertension. N Engl J Med. 1987;317:350&#x2013;7.</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJM198708063170605</ArticleId></ArticleIdList></Reference><Reference><Citation>Whelton PK, Carey RM, Aronow WS, Casey DE Jr, Collins KJ, Dennison Himmelfarb C, et al. 2017 ACC/AHA/AAPA/ABC/ACPM/AGS/APhA/ASH/ASPC/NMA/PCNA guideline for the prevention, detection, evaluation, and management of high blood pressure in adults: executive summary: a report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. J Am Coll Cardiol. 2018;71:2199&#x2013;269.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jacc.2017.11.005</ArticleId></ArticleIdList></Reference><Reference><Citation>Chen L, Pei JH, Kuang J, Chen HM, Chen Z, Li ZW, et al. Effect of lifestyle intervention in patients with type 2 diabetes: a meta-analysis. Metabolism. 2015;64:338&#x2013;47.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.metabol.2014.10.018</ArticleId></ArticleIdList></Reference><Reference><Citation>Baker WL, Smyth LR, Riche DM, Bourret EM, Chamberlin KW, White WB. Effects of sodium-glucose co-transporter 2 inhibitors on blood pressure: a systematic review and meta-analysis. J Am Soc Hypertens. 2014;8:262&#x2013;75.e269.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jash.2014.01.007</ArticleId></ArticleIdList></Reference><Reference><Citation>Marso SP, Daniels GH, Brown-Frandsen K, Kristensen P, Mann JF, Nauck MA, et al. Liraglutide and cardiovascular outcomes in type 2 diabetes. N Engl J Med. 2016;375:311&#x2013;22.</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJMoa1603827</ArticleId></ArticleIdList></Reference><Reference><Citation>Higashikuni Y, Liu W, Numata G, Tanaka K, Fukuda D, Tanaka Y, et al. NLRP3 Inflammasome activation through heart-brain interaction initiates cardiac inflammation and hypertrophy during pressure overload. Circulation. https://doi.org/10.1161/CIRCULATIONAHA.122.060860 . (In press).</Citation></Reference><Reference><Citation>Ridker PM, Everett BM, Thuren T, MacFadyen JG, Chang WH, Ballantyne C, et al. Antiinflammatory therapy with canakinumab for atherosclerotic disease. N Engl J Med. 2017;377:1119&#x2013;31.</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJMoa1707914</ArticleId></ArticleIdList></Reference><Reference><Citation>Rothman AM, MacFadyen J, Thuren T, Webb A, Harrison DG, Guzik TJ, et al. Effects of interleukin-1beta inhibition on blood pressure, incident hypertension, and residual inflammatory risk: a secondary analysis of CANTOS. Hypertension. 2020;75:477&#x2013;82.</Citation><ArticleIdList><ArticleId IdType="doi">10.1161/HYPERTENSIONAHA.119.13642</ArticleId></ArticleIdList></Reference><Reference><Citation>Krishnan SM, Ling YH, Huuskes BM, Ferens DM, Saini N, Chan CT, et al. Pharmacological inhibition of the NLRP3 inflammasome reduces blood pressure, renal damage, and dysfunction in salt-sensitive hypertension. Cardiovasc Res. 2019;115:776&#x2013;87.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/cvr/cvy252</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>